Our studies provide the first evidence that pharmacological enhancement of adaptive stress response has encouraging therapeutic potential for the treatment of CAVD, as well as uncovering a previously unrecognized role of Nox4 in AV calcification. The gene discussed is NOX4; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.